Nifty
Sensex
:
:
25758.00
84391.27
-81.65 (-0.32%)
-275.01 (-0.32%)

Pharmaceuticals & Drugs

Rating :
62/99

BSE: 543748 | NSE: AARTIPHARM

708.15
10-Dec-2025
  • Open
  • High
  • Low
  • Previous Close
  •  723.7
  •  725.8
  •  702.95
  •  724.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  77791
  •  55641554.95
  •  971
  •  557.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,403.32
  • 26.71
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,936.64
  • 0.71%
  • 3.13

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 42.88%
  • 2.98%
  • 35.39%
  • FII
  • DII
  • Others
  • 8.02%
  • 6.10%
  • 4.63%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 2.83

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 6.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 12.08

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Earnings Forecasts:

(Updated: 06-12-2025)
Description
2024
2025
2026
2027
Adj EPS
30.06
29.79
35.14
P/E Ratio
23.56
23.77
20.15
Revenue
2086
2144.5
2523.6
EBITDA
464.37
489.1
579.8
Net Income
272.4
270.25
313.85
ROA
9.93
P/B Ratio
3.23
3.14
2.78
ROE
14.54
12.45
13
FCFF
-87.84
125.1
101.9
FCFF Yield
-1.32
1.87
1.53
Net Debt
356.91
BVPS
219.55
225.8
254.9

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
418.34
458.03
-8.67%
386.19
555.49
-30.48%
563.78
505.77
11.47%
537.78
448.69
19.86%
Expenses
343.62
364.35
-5.69%
290.95
459.03
-36.62%
418.15
388.25
7.70%
409.17
353.01
15.91%
EBITDA
74.72
93.67
-20.23%
95.24
96.46
-1.26%
145.63
117.51
23.93%
128.61
95.68
34.42%
EBIDTM
17.86%
20.45%
24.66%
17.36%
25.83%
23.23%
23.91%
21.32%
Other Income
0.05
4.48
-98.88%
1.60
2.22
-27.93%
-1.61
2.03
-
5.03
1.39
261.87%
Interest
10.67
5.51
93.65%
6.80
4.83
40.79%
6.58
4.68
40.60%
9.97
4.48
122.54%
Depreciation
24.77
20.88
18.63%
22.79
20.17
12.99%
22.82
19.12
19.35%
23.04
18.77
22.75%
PBT
39.34
71.77
-45.19%
67.25
73.68
-8.73%
114.62
95.75
19.71%
100.63
73.82
36.32%
Tax
10.77
17.14
-37.16%
15.95
18.22
-12.46%
26.28
30.50
-13.84%
26.64
21.05
26.56%
PAT
28.57
54.62
-47.69%
51.30
55.45
-7.48%
88.34
65.25
35.39%
73.99
52.76
40.24%
PATM
6.83%
11.93%
13.28%
9.98%
15.67%
12.90%
13.76%
11.76%
EPS
3.08
6.03
-48.92%
5.46
6.12
-10.78%
9.75
7.20
35.42%
8.16
5.82
40.21%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Net Sales
1,906.09
2,115.07
1,852.61
1,945.23
1,199.94
Net Sales Growth
-3.14%
14.17%
-4.76%
62.11%
 
Cost Of Goods Sold
933.25
1,127.88
1,020.71
1,169.76
637.67
Gross Profit
972.84
987.20
831.89
775.48
562.27
GP Margin
51.04%
46.67%
44.90%
39.87%
46.86%
Total Expenditure
1,461.89
1,650.70
1,466.56
1,603.18
994.67
Power & Fuel Cost
-
81.32
84.03
75.10
90.00
% Of Sales
-
3.84%
4.54%
3.86%
7.50%
Employee Cost
-
148.65
128.03
121.32
85.20
% Of Sales
-
7.03%
6.91%
6.24%
7.10%
Manufacturing Exp.
-
141.94
105.52
98.78
145.95
% Of Sales
-
6.71%
5.70%
5.08%
12.16%
General & Admin Exp.
-
49.08
40.51
30.20
8.13
% Of Sales
-
2.32%
2.19%
1.55%
0.68%
Selling & Distn. Exp.
-
79.71
68.88
74.83
27.38
% Of Sales
-
3.77%
3.72%
3.85%
2.28%
Miscellaneous Exp.
-
22.12
18.88
33.20
0.34
% Of Sales
-
1.05%
1.02%
1.71%
0.03%
EBITDA
444.20
464.37
386.05
342.05
205.27
EBITDA Margin
23.30%
21.96%
20.84%
17.58%
17.11%
Other Income
5.07
10.12
4.90
2.32
4.19
Interest
34.02
26.90
17.21
21.05
11.96
Depreciation
93.42
86.90
73.24
62.54
42.12
PBT
321.84
360.69
300.49
260.77
155.38
Tax
79.64
88.28
83.59
67.28
33.13
Tax Rate
24.75%
24.48%
27.82%
25.80%
21.32%
PAT
242.20
272.40
216.90
193.49
122.25
PAT before Minority Interest
242.20
272.40
216.90
193.49
122.25
Minority Interest
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.71%
12.88%
11.71%
9.95%
10.19%
PAT Growth
6.19%
25.59%
12.10%
58.27%
 
EPS
26.73
30.07
23.94
21.36
13.49

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Shareholder's Funds
1,989.91
1,757.04
1,558.49
1,386.48
Share Capital
45.32
45.31
45.31
0.25
Total Reserves
1,942.86
1,711.50
1,513.17
1,340.91
Non-Current Liabilities
259.45
130.68
84.91
72.76
Secured Loans
103.56
0.04
0.18
0.55
Unsecured Loans
0.00
0.00
0.00
0.00
Long Term Provisions
8.12
6.06
5.36
0.00
Current Liabilities
657.05
694.39
600.62
580.67
Trade Payables
277.83
378.32
339.50
214.59
Other Current Liabilities
73.54
45.84
38.33
11.89
Short Term Borrowings
292.80
263.92
213.78
337.73
Short Term Provisions
12.88
6.31
9.01
16.46
Total Liabilities
2,906.41
2,582.11
2,244.02
2,039.91
Net Block
1,136.57
1,033.33
925.84
782.09
Gross Block
1,795.66
1,609.29
1,431.25
1,225.00
Accumulated Depreciation
659.09
575.96
505.41
442.90
Non Current Assets
1,584.24
1,236.46
1,081.02
1,011.75
Capital Work in Progress
374.35
136.92
101.87
187.37
Non Current Investment
29.24
36.78
35.52
32.23
Long Term Loans & Adv.
44.08
29.44
17.78
10.07
Other Non Current Assets
0.00
0.00
0.00
0.00
Current Assets
1,322.17
1,345.64
1,163.01
1,028.15
Current Investments
47.56
70.39
50.99
0.00
Inventories
587.58
642.86
602.04
475.45
Sundry Debtors
575.40
519.34
450.10
376.66
Cash & Bank
8.65
24.07
12.19
83.27
Other Current Assets
102.98
17.01
7.70
10.74
Short Term Loans & Adv.
87.28
71.97
39.98
82.03
Net Current Assets
665.12
651.25
562.38
447.48
Total Assets
2,906.41
2,582.10
2,244.03
2,039.90

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Cash From Operating Activity
331.56
216.35
250.12
-43.70
PBT
360.69
300.49
260.77
155.38
Adjustment
121.47
94.65
83.35
52.41
Changes in Working Capital
-86.07
-121.85
-31.63
-230.36
Cash after chg. in Working capital
396.09
273.29
312.50
-22.57
Interest Paid
0.00
0.00
0.00
0.00
Tax Paid
-64.53
-56.94
-62.38
-21.13
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
Cash From Investing Activity
-413.90
-214.56
-157.80
-138.74
Net Fixed Assets
-413.07
-203.41
-117.58
Net Investments
4.63
-6.18
-15.61
Others
-5.46
-4.97
-24.61
Cash from Financing Activity
65.44
9.72
-163.46
260.38
Net Cash Inflow / Outflow
-16.90
11.51
-71.15
77.94
Opening Cash & Equivalents
23.63
12.12
83.27
5.33
Closing Cash & Equivalent
6.73
23.63
12.12
83.27

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Book Value (Rs.)
219.36
193.85
171.97
53646.60
ROA
9.93%
8.99%
9.03%
11.98%
ROE
14.55%
13.08%
13.35%
18.23%
ROCE
17.59%
16.75%
16.11%
19.40%
Fixed Asset Turnover
1.24
1.22
1.46
0.98
Receivable days
94.46
95.50
77.57
114.57
Inventory Days
106.17
122.63
101.09
144.62
Payable days
106.17
128.34
86.45
61.41
Cash Conversion Cycle
94.46
89.79
92.21
197.78
Total Debt/Equity
0.20
0.15
0.14
0.25
Interest Cover
14.41
18.46
13.39
13.99

Annual Reports:

News Update:


  • Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility in Gujarat
    3rd Sep 2025, 16:42 PM

    The company has successfully obtained all the necessary permissions and approvals to start the facility

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.